Skip to main content
Fig. 1 | Journal of Inflammation

Fig. 1

From: Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy

Fig. 1

The effects of orally (PO) dosed tofacitinib (Tofa; 5–30 mg/kg TID) on the disease activity index (a), and its components, body weight (b), stool consistency (c) and occult blood (d), following oxazolone (Oxa) challenge to sensitized mice. Data are expressed as mean ± SEM (n = 8–35). **** p < 0.0001 vs. Veh/Veh (Student’s t-test), # p = 0.02, ## p = 0.003, ### p = 0.0008 and #### p < 0.0001 vs. Veh/Oxa (One-way ANOVA, Fisher’s LSD post-hoc test)

Back to article page